7.94
+0.91(+12.94%)
Currency In USD
Address
142 Sansome Street
San Francisco, CA 94104
United States of America
Phone
415 432 9270
Website
Sector
Healthcare
Industry
Biotechnology
Employees
70
First IPO Date
November 11, 2019
| Name | Title | Pay | Year Born |
| Mr. Rohan Palekar | Chief Executive Officer & Director | 1.06M | 1966 |
| Mr. Quoc Le-Nguyen | Chief Technical Officer | 702,871 | 1968 |
| Dr. Harry Mansbach M.D. | Chief Medical Officer | 732,871 | 1965 |
| Ms. Melissa Abel | Senior Vice President of Commercial Strategy | 0 | N/A |
| Mr. Paul Shin | Senior Vice President of R&D Operations | 0 | N/A |
| Ms. Annie J. Chang M.B.A. | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Mr. Francis W. Sarena | Chief Operating Officer | 0 | 1971 |
| Mr. Shiva K. Natarajan CPA | Senior Vice President of Finance & Principal Accounting Officer | 0 | 1966 |
| Ms. Amanda Kurihara | Vice President of People & Culture | 0 | N/A |
| Mr. Ryan Stephen Martins | Chief Financial Officer | 0 | 1979 |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.